stockrowTravere Therapeutics, Inc.
TVTX Healthcare Biotechnology
Travere Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $490.7 million, up 110.5% from fiscal 2024.
- Revenue
- +36.2%
- EPS
- −290.7%
- Free cash flow
- +6,379.8%
- Total debt
- +93.8%
Quarter to September 2026, against a year earlier
Follow TVTX
Alert me
Travere Therapeutics, Inc. (TVTX) Total debt
Travere Therapeutics, Inc.'s total debt at the end of fiscal 2025 was $311.7M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $603.5M. Over the past ten years it has ranged from $43.8M (fiscal 2015) to $377.3M (fiscal 2023); the current reading is higher than 82% of that period. Travere Therapeutics, Inc. ranks 24th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $311.7M | 0.46% |
| FY2024 | $310.3M | (17.75%) |
| FY2023 | $377.3M | 0.46% |
| FY2022 | $375.5M | 65.74% |
| FY2021 | $226.6M | 5.22% |
| FY2020 | $215.3M | 5.11% |
| FY2019 | $204.9M | 5.01% |
| FY2018 | $195.1M | 332.79% |
| FY2017 | $45.1M | 1.47% |
| FY2016 | $44.4M | 1.50% |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $603.5M | 0.12% |
| Jun 2026 | $602.8M | 93.15% |
| Mar 2026 | $312.1M | 0.11% |
| Dec 2025 | $311.7M | 0.11% |
| 42 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| TVTX Travere Therapeutics, Inc. | $603.5M |
| CRSP CRISPR Therapeutics AG compare | $586.9M |
| COGT Cogent Biosciences, Inc. compare | $223.5M |
| LEGN Legend Biotech Corporation Sponsored ADR compare | $156.4M |
| ERAS Erasca, Inc. compare | $56.8M |
| DFTX Definium Therapeutics, Inc. compare | $36.5M |
| EWTX Edgewise Therapeutics, Inc. compare | $5.6M |
| DNTH Dianthus Therapeutics, Inc. compare | $670.0K |
| MANE Veradermics Incorporated compare | — |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on TVTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement